fda compounding glp-1 enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Drugmakers battle pharmacies over compounded

As Lilly explained in the presentation, a decision was made to extend the trial to 104 weeks for about 500 patients

Retatrutide is an injectable weight-loss and diabetes drug developed by Eli Lilly , currently in Phase 3 clinical trials

doi: 10.3389/fendo.2019.00728

Bottom line If you are comparing Wegovy, Ozempic, Zepbound, Saxenda, Victoza, and Trulicity, the biggest takeaway is simple: the best medication depends entirely on the clinical goal

Molecular metabolism 1(50):101115 Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, Pique-Regi R, Dong XC, Chen YE, Willer C, Liu W (2020) Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping